---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-172277"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:38:48.777763+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Verrica amends credit agreement with OrbiMed; revenue test deferred to Sept 30, 2024

## Summary
- Amendment to Credit Agreement moves revenue test start from earlier date to September 30, 2024.
- $500,000 amendment fee paid to lenders in connection with the amendment.
- Revenue test determines if principal payments (including premium) are required based on YCANTH net revenue.
- No other terms of the Credit Agreement were changed.

## SEC filing metadata
- accession: 0001193125-24-172277
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312524172277/0001193125-24-172277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312524172277/d844833d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-172277
- JSON: https://secwatch.observer/filing/0001193125-24-172277.json
- Plain text: https://secwatch.observer/filing/0001193125-24-172277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.